Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Novartis
UBS
McKesson
Chubb
Boehringer Ingelheim
Healthtrust
US Army
Daiichi Sankyo
QuintilesIMS

Generated: October 19, 2017

DrugPatentWatch Database Preview

PROTONIX IV Drug Profile

« Back to Dashboard

What is the patent landscape for Protonix Iv, and what generic Protonix Iv alternatives are available?

Protonix Iv is a drug marketed by Wyeth Pharms Inc and is included in one NDA. There are three patents protecting this drug.

This drug has fifty-eight patent family members in forty countries and two supplementary protection certificates in two countries.

The generic ingredient in PROTONIX IV is pantoprazole sodium. There are forty-seven drug master file entries for this compound. Sixty-two suppliers are listed for this compound. Additional details are available on the pantoprazole sodium profile page.

Summary for Tradename: PROTONIX IV

US Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: see list2
Bulk Api Vendors: see list80
Clinical Trials: see list13
Patent Applications: see list3,676
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:PROTONIX IV at DailyMed

Pharmacology for Tradename: PROTONIX IV

Drug ClassProton Pump Inhibitor
Mechanism of ActionProton Pump Inhibitors
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Wyeth Pharms Inc
PROTONIX IV
pantoprazole sodium
INJECTABLE;IV (INFUSION)020988-001Mar 22, 2001APRXYesYes► Subscribe► SubscribeY► Subscribe
Wyeth Pharms Inc
PROTONIX IV
pantoprazole sodium
INJECTABLE;IV (INFUSION)020988-001Mar 22, 2001APRXYesYes► Subscribe► SubscribeY► Subscribe
Wyeth Pharms Inc
PROTONIX IV
pantoprazole sodium
INJECTABLE;IV (INFUSION)020988-001Mar 22, 2001APRXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: PROTONIX IV

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Wyeth Pharms Inc
PROTONIX IV
pantoprazole sodium
INJECTABLE;IV (INFUSION)020988-001Mar 22, 2001► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: PROTONIX IV

Country Document Number Estimated Expiration
Denmark1339430► Subscribe
Georgia, Republic ofP20053461► Subscribe
Germany60132108► Subscribe
European Patent Office1339430► Subscribe
Austria381946► Subscribe
MexicoPA03004548► Subscribe
BrazilPI0115483► Subscribe
Iceland2971► Subscribe
Portugal1339430► Subscribe
Serbia52024► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: PROTONIX IV

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0032Belgium► SubscribePRODUCT NAME: PANTOPRAZOL. NATR. SESQUIHYDRAS PANTOPRAZOLE; NAT. REGISTRATION NO/DATE: 127 IS 98 F 3 19960222; FIRST REGISTRATION: SE 12131 19940506
C/GB96/056United Kingdom► SubscribePRODUCT NAME: PANTOPRAZOLE AND ITS SALTS, HYDRATES AND HYDRATES OF ITS SALTS; REGISTERED: SE SE12131 19940506; UK 04889/0010 19960604
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Merck
Healthtrust
QuintilesIMS
Express Scripts
Boehringer Ingelheim
Moodys
Cerilliant
Harvard Business School
Fuji
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot